MultiCell Licensee to Market Cell Lines at Two Major Conferences
Tuesday September 7, 9:01 am ET
WARWICK, R.I.--(BUSINESS WIRE)--Sept. 7, 2004--MultiCell Technologies, Inc. (OTCBB:MUCL - News), the world's foremost supplier of non-tumorigenic functional immortalized hepatocytes, announced today that XenoTech LLC, MultiCell's marketing and manufacturing licensee, will present MultiCell's Fa2n-4 and EA1C-35 immortalized human hepatocyte lines at two targeted conferences in September.
XenoTech will exhibit at the Society for Biomolecular Screening meeting September 11-15, 2004 in Kissimmee, Florida at Booth number 1029.
Concurrently, XenoTech will be sponsoring a reception at the Land O' Lakes 6th Annual International Conference on Drug Metabolism and Applied Pharmacokinetics September 13-17, 2004 at the Devil's Head Resort in Merrimac, Wisconsin.
MultiCell's immortalized human hepatocyte lines have the potential to save pharmaceutical companies years of time and millions of dollars during preclinical development and testing stages. A key reason is that they can help solve the problem of supply and variability that restrict the use of harvested human liver cells for enzyme induction, cellular toxicity assays and other in vitro screening. Also, because hepatocytes express drug-metabolizing enzymes that metabolize or detoxify drugs or substances ingested into the body, they can help predict the effect of a compound on human livers. MultiCell's cell lines are especially sensitive to compounds that alter the expression of CYP3A4, an essential feature of in vitro model systems when studying the impact of one drug on another.
Drug failures or FDA rejections due to hepatotoxicity and/or drug-drug interactions cost the pharmaceutical industry about $2 billion each year and it costs about $900 million to develop and test a new medicine.
MultiCell, through XenoTech, provides its patented, non-tumorigenic, fully functional hepatic cells and cell lines plated (6 to 96 wells) or in vials to pharmaceutical companies for drug discovery and development. For pricing and delivery information, contact XenoTech LLC of Lenexa, KS, telephone 913-GET-P450 or see www.xenotechllc.com.
MultiCell's corporate and research headquarters are at 55 Access Road, Suite 700, in Warwick, Rhode Island.
For more information about MultiCell and its majority-owned Xenogenics subsidiary, which owns all rights to the Sybiol(TM) synthetic bio-liver device, call 401-738-7560 or see www.multicelltech.com.
MultiCell also announces that a shareholder update/ review of the third quarter of fiscal 2004 is now available on the investor relations section of the website.
The matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. These risks are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission including the Company's Annual Report, Quarterly Reports and other periodic filings. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
--------------------------------------------------------------------------------
Contact:
MultiCell Technologies Inc.
Jerry Newmin, 401-738-7560
--------------------------------------------------------------------------------
Source: MultiCell Technologies Inc.
biz.yahoo.com |
